How to Get a GLP-1 Prescription Online: 4 Steps

Step 1: Confirm Your Clinical Eligibility

Before starting a telehealth visit, verify that you meet the clinical criteria the prescribing physician will evaluate. FDA labeling and the Endocrine Society 2024 guidelines specify that GLP-1 receptor agonists for chronic weight management are indicated for adults with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

Your BMI alone does not guarantee a prescription. Physicians also assess contraindications. Both semaglutide and tirzepatide carry FDA boxed warnings regarding medullary thyroid carcinoma risk in rodent studies. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) disqualifies candidates. A history of pancreatitis may also lead a prescriber to choose an alternative therapy.

Gather these items before your visit: your current height and weight, a list of all medications and supplements, any recent lab results (A1c, fasting glucose, lipid panel, comprehensive metabolic panel), and your medical history with attention to thyroid disease, pancreatitis, and gastroparesis. Having these ready shortens the consultation and reduces the chance of a follow-up delay. Some platforms ask you to upload labs taken within the past 90 days; others order new bloodwork after intake.

If your BMI falls between 25 and 26.9, you will not qualify for FDA-approved branded GLP-1 medications for obesity. However, certain providers may prescribe off-label for patients with strong metabolic risk factors. That decision rests with the individual clinician, and off-label use is not covered by most commercial insurance plans.

Step 2: Complete a Telehealth Medical Evaluation

Once you confirm basic eligibility, the next step is scheduling or completing a synchronous medical evaluation. The American Telemedicine Association and state medical boards require that a licensed prescriber establish a provider-patient relationship before writing a prescription for a controlled or high-cost medication.

Most platforms offer two formats: an asynchronous intake questionnaire followed by a video or phone call, or a fully synchronous video consultation. The asynchronous portion typically takes 10 to 15 minutes and covers demographics, weight history, prior weight-loss attempts, current medications, and medical history. The synchronous component, whether by video or phone, usually runs 15 to 30 minutes.

During the live evaluation, the physician or nurse practitioner will review your intake, discuss your weight-management goals, explain how GLP-1 receptor agonists work, and outline the dose-escalation schedule. Semaglutide (Wegovy), for example, starts at 0.25 mg weekly for the first four weeks, increases to 0.5 mg for weeks 5 through 8, then to 1.0 mg, 1.7 mg, and the maintenance dose of 2.4 mg by week 17. Tirzepatide (Zepbound) follows a separate five-step titration beginning at 2.5 mg weekly and escalating to a maximum of 15 mg by week 20.

The clinician will also screen for contraindications the intake might have missed. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "The telehealth evaluation for GLP-1 therapy should be just as rigorous as an in-person visit. We screen for thyroid history, gastroparesis, gallbladder disease, and psychiatric conditions, because these medications are not one-size-fits-all." This screening is essential. Rushing past it creates safety risks that no convenience gain justifies.

Expect your clinician to ask about prior use of phentermine, naltrexone-bupropion (Contrave), or orlistat (Xenical/Alli). Your response history shapes whether a GLP-1 is the right next step or whether combination therapy should be considered. The prescriber may also order baseline labs if you have not completed bloodwork recently, which can add 3 to 7 days before a prescription is written.

Step 3: Receive Your Prescription After Physician Review

After the evaluation, the prescribing physician reviews all clinical data and makes a prescribing decision. If approved, the prescription is transmitted electronically to a pharmacy. This step can happen the same day as your visit or within 24 to 48 hours if lab results are pending.

The prescriber selects from several FDA-approved options depending on your clinical profile, insurance formulary, and cost considerations. For weight management specifically, the two FDA-approved GLP-1 receptor agonists are semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound). For type 2 diabetes, options include semaglutide 0.5/1/2 mg (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza), though these carry diabetes-specific labeling rather than an obesity indication.

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg achieved 14.9% mean body weight loss at 68 weeks compared with 2.4% in the placebo group. The SURMOUNT-1 trial (N=2,539) showed that tirzepatide at the highest dose (15 mg) produced 20.9% mean weight loss versus 3.1% with placebo over 72 weeks. These numbers matter because they give you and your provider a data-driven framework for setting realistic expectations.

A third statistic worth noting: in STEP-2 (N=1,210), which focused on adults with type 2 diabetes and obesity, semaglutide 2.4 mg achieved a mean A1c reduction of 1.6 percentage points and 9.6% body weight loss at 68 weeks. For patients managing both diabetes and excess weight, this dual benefit often makes the prescribing decision straightforward.

Your prescription will specify the starting dose, the escalation schedule, and the total number of pens or vials. Most prescriptions are written for 30-day supplies with refill authorization aligned to the dose-titration timeline. You should receive a copy of the prescription electronically, and many telehealth platforms provide a patient portal where you can track its status.

If the prescriber determines that a GLP-1 is not appropriate for you, they should document the reasoning and suggest alternatives. This might include naltrexone-bupropion, phentermine-topiramate, or referral to a bariatric surgery evaluation depending on your BMI and medical history. A denial is not the end of the process. It is a clinical judgment that protects your safety.

Step 4: Set Up Pharmacy Fulfillment and Medication Delivery

The final step is getting the medication into your hands. Telehealth platforms typically route prescriptions through one of three channels: a retail pharmacy (CVS, Walgreens, Walmart), a specialty pharmacy, or a direct-to-patient mail-order pharmacy affiliated with the platform.

Retail pharmacies are the most familiar option but face frequent supply constraints. The FDA drug shortage database has listed various Wegovy dose strengths intermittently since 2022. If your local pharmacy cannot fill the prescription, ask the pharmacist to check inventory at nearby locations or request a transfer. Specialty pharmacies tend to have more reliable access to branded GLP-1 products because they maintain dedicated inventory agreements with manufacturers.

Mail-order delivery through the telehealth platform itself is often the most streamlined channel. Medications arrive in temperature-controlled packaging (semaglutide and tirzepatide require refrigeration at 36°F to 46°F before first use), typically within 3 to 5 business days. After first use, semaglutide pens can be stored at room temperature (up to 86°F) for 28 days, and tirzepatide pens can be stored at room temperature for 21 days.

Insurance and Cost Navigation

Insurance coverage for GLP-1 medications varies significantly by plan. According to the Obesity Action Coalition, roughly 40 to 50% of commercial plans cover at least one FDA-approved anti-obesity medication, but coverage often requires prior authorization, documentation of failed lifestyle interventions, and a qualifying BMI with comorbidities.

If your plan denies coverage, several options remain. Manufacturer savings programs can reduce branded costs: Novo Nordisk offers a savings card for Wegovy that may lower copays to as little as $0 for commercially insured patients for a limited period. Lilly provides a similar program for Zepbound. Without any insurance or savings card, branded GLP-1s run approximately $900 to $1,350 per month at most retail pharmacies.

Your telehealth provider should assist with prior authorization paperwork. This involves submitting clinical documentation to your insurer, including your BMI, comorbidity diagnoses, prior weight-loss attempts, and lab results. The American Association of Clinical Endocrinology (AACE) consensus statement recommends that insurers cover anti-obesity medications when prescribed according to evidence-based guidelines. Appeals of initial denials succeed in a meaningful percentage of cases when supported by proper clinical documentation.

What to Expect in the First 4 Weeks

Starting a GLP-1 involves a titration period designed to minimize gastrointestinal side effects. During the first four weeks on semaglutide (0.25 mg weekly), common side effects include nausea (reported by 44% of participants in STEP-1), diarrhea (30%), vomiting (24%), and constipation (24%). Most of these effects are mild to moderate and diminish as the body adjusts.

Practical strategies reduce discomfort: eat smaller meals, avoid high-fat foods, stay hydrated, and time your injection for the evening so that any nausea peaks during sleep. Your telehealth provider should schedule a follow-up check-in at weeks 2 to 4 to assess tolerability and confirm readiness for dose escalation. If nausea is severe, the provider may extend the time at the starting dose before escalating.

Weight loss during the first month is typically modest: 1 to 3% of body weight. The clinically significant results seen in trials, 14.9% with semaglutide and up to 20.9% with tirzepatide, accumulate over 16 to 20 months of continued treatment. Setting this expectation early prevents premature discontinuation, which the STEP-4 trial (N=902) showed leads to regain of roughly two-thirds of lost weight within one year of stopping.

Choosing a Telehealth Platform

Not all telehealth platforms operate the same way. When evaluating your options, confirm these elements: the platform employs or contracts board-certified physicians or nurse practitioners licensed in your state, it uses a synchronous video or phone evaluation rather than a questionnaire-only model, it provides ongoing follow-up visits (not just an initial prescription), and it has a clear policy for managing side effects and dose adjustments.

The Federation of State Medical Boards maintains guidelines requiring that telehealth prescribers meet the same standard of care as in-person clinicians. A platform that promises a GLP-1 prescription without a meaningful clinical evaluation is a red flag. The American Medical Association's policy on telehealth reinforces that prescribing decisions must be based on adequate clinical information, not on patient demand alone.

Look for platforms that include ongoing monitoring: monthly or quarterly check-ins, weight tracking, lab review at 3- and 6-month intervals, and access to a care team for questions between visits. GLP-1 therapy is not a set-and-forget treatment. It requires clinical oversight for safe dose titration, side-effect management, and long-term maintenance planning.

As Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "The prescribing of GLP-1 receptor agonists should always occur within a comprehensive treatment plan that includes nutritional counseling, physical activity guidance, and regular clinical monitoring." This standard applies whether the encounter happens in a clinic or over video.

Red Flags to Avoid

Certain practices should prompt you to look elsewhere. Platforms that guarantee a prescription before evaluation, offer GLP-1s without confirming BMI criteria, skip contraindication screening, or do not provide follow-up care are operating below the standard of care set by the Endocrine Society and AACE.

Compounded semaglutide is another area requiring caution. The FDA issued a safety communication warning that compounded versions of semaglutide have not undergone FDA review for safety, efficacy, or quality. While compounding pharmacies fill a legitimate role during drug shortages, patients should understand the distinction between FDA-approved products and compounded alternatives. Ask whether the product is the FDA-approved branded version or a compounded formulation, and make sure the answer is documented in your records.

Patients taking insulin, sulfonylureas, or other glucose-lowering medications need their prescriber to coordinate dose adjustments to avoid hypoglycemia. A telehealth platform that does not ask about concurrent diabetes medications is missing a basic safety step outlined in the ADA Standards of Care.

The first injection of semaglutide 0.25 mg or tirzepatide 2.5 mg should be administered into the abdomen, thigh, or upper arm, rotating sites weekly to reduce injection-site reactions.